Prevalence of Nitroimidazole-Refractory Giardiasis Acquired in Different World Regions, Sweden, 2008–2020

IF 7.2 2区医学 Q1 IMMUNOLOGY

Emerging Infectious Diseases Pub Date : 2025-05-16 DOI:10.3201/eid3106.250076

Karin A. Ydsten, Joanna Nederby Öhd, Urban Hellgren, Hilmir Asgeirsson

引用次数: 0

Abstract

Treatment-refractory giardiasis is an emerging clinical problem. Of 4,285 giardiasis cases identified during 2008–2020 in Stockholm, Sweden, 102 (2.4%) were nitroimidazole-refractory. Among cases acquired in India, the percentage was high (64/545 [12%]) and increased over time. The region of acquisition needs to be taken into consideration when managing patients.

查看原文本刊更多论文

2008-2020年瑞典不同地区获得性硝基咪唑难治性贾第虫病流行情况

难治性贾第虫病是一个新出现的临床问题。在瑞典斯德哥尔摩2008-2020年期间发现的4285例贾第虫病病例中，102例（2.4%）为硝基咪唑难治病例。在印度获得的病例中，百分比很高（64/545[12%]），并且随着时间的推移而增加。在管理患者时，需要考虑到获得区域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Emerging Infectious Diseases 医学-传染病学

CiteScore

17.30

自引率

1.70%

发文量

505

审稿时长

1 months

期刊介绍： Emerging Infectious Diseases is a monthly open access journal published by the Centers for Disease Control and Prevention. The primary goal of this peer-reviewed journal is to advance the global recognition of both new and reemerging infectious diseases, while also enhancing our understanding of the underlying factors that contribute to disease emergence, prevention, and elimination. Targeted towards professionals in the field of infectious diseases and related sciences, the journal encourages diverse contributions from experts in academic research, industry, clinical practice, public health, as well as specialists in economics, social sciences, and other relevant disciplines. By fostering a collaborative approach, Emerging Infectious Diseases aims to facilitate interdisciplinary dialogue and address the multifaceted challenges posed by infectious diseases.